Johnson &a; Johnson Development Corporation
Johnson &a; Johnson Development Corporation, a venture capital subsidiary, finances technology companies focused on patient health.
Business Model: B2C B2B
Revenue: $16.3M
Employees: 2-10
Rankings
Detailed Johnson &a; Johnson Development Corporation Information
Geographic Data
Address: 410 George St
City: New Brunswick
State: NJ
Zip: 08901
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Johnson &a; Johnson Development Corporation (JJDC) is the venture capital subsidiary of Johnson &a; Johnson. JJDC is comprised of experts and leaders in the health care and technology venture communities who identify early market indicators, health care trends, and strategic investment opportunities. Unlike traditional venture capital firms, JJDC determines the success of an investment’s performance not only in financial returns, but also in the viability of providing strategic growth options for Johnson &a; Johnson. JJDC plays an integral role in the identification of new business opportunities outside of Johnson &a; Johnson’s traditional portfolio and market presence. JJDC identifies new market opportunities and develops new businesses in emergent health care sectors while also creating support venture investments in alignment with the strategic objectives of Johnson &a; Johnson operating companies.
Contact Phone:
+17325243214
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 9/2002 | CellGate | Series D | 10M |
| 6/2003 | Orqis Medical | Series C | 25M |
| 10/2007 | Direct Flow Medical | Series B | 27M |
| 3/2004 | BioRexis | Series B | 30M |
| 7/2007 | ViaCyte | Series C | 0 |
| 7/2002 | Transvascular | Series D | 10.8M |
| 3/2015 | PhaseBio Pharmaceuticals | Series C | 0 |
| 11/2013 | Biocartis | Series E | 0 |
| 1/2011 | Zeo | Series C | 0 |
| 7/2013 | ReVision Optics | Series E | 55M |
| 5/2005 | Mazor Robotics | Series B | 10M |
| 2/2017 | Fusion Pharmaceuticals | Series A | 0 |
| 12/2000 | Sleep Solutions | Series D | 8M |
| 6/2014 | Navitor Pharmaceuticals | Series A | 23.5M |
| 5/2014 | Rodin Therapeutics | Series A | 12.9M |
| 6/2013 | Rodin Therapeutics | Seed Round | - |
| 10/2007 | Syntaxin | Series B | 32M |
| 6/2009 | CoAxia | Series D | 21.5M |
| 10/2007 | Tengion | Series C | 33M |
| 6/2006 | Tengion | Series B | 50M |
| 10/2003 | Critical Therapeutics,Inc. | Series B | 56M |
| 8/2011 | NeuroPace | Venture Round | 0 |
| 7/2013 | NeuroPace | Venture Round | 18M |
| 1/2012 | iScience Interventional | Venture Round | 2.8M |
| 1/2015 | Willow | Series A | 15M |
| 6/2000 | iKnowMed | Series C | 30.7M |
| 7/2003 | InSound Medical | Series D | 6.5M |
| 10/2007 | PhaseBio Pharmaceuticals | Venture Round | 6.6M |
| 10/2005 | Light Sciences Oncology | Series A | 35M |
| 4/2013 | Catalyst Biosciences | Post-IPO Equity | 5.1M |
| 11/2016 | ReVision Optics | Venture Round | 32M |
| 12/2009 | Genocea Biosciences | Series B | 25.7M |
| 10/2012 | Genocea Biosciences | Series C | 30M |
| 8/2005 | Tengion | Series A | 39M |
| 7/2011 | Binx Health | Series B | 27.1M |
| 10/2013 | Merus | Series B | 42.2M |
| 12/2008 | Catalyst Biosciences | Post-IPO Equity | 40M |
| 3/2013 | CoStim Pharmaceuticals | Series A | 22M |
| 7/2011 | Nevro | Series B | 58M |
| 6/2012 | Astute Medical | Series C | 40.4M |
| 1/2011 | Genocea Biosciences | Series B | 35M |
| 3/2009 | GI Dynamics | Series C | 0 |
| 9/2005 | Biolex Therapeutics | Series B | 36M |
| 5/2007 | Biolex Therapeutics | Series C | 30M |
| 8/2008 | Brainsgate | Series C | 27.5M |
| 4/2007 | CymaBay Therapeutics | Series D | 32M |
| 3/2013 | Nevro | Series C | 0 |
| 4/2012 | Direct Flow Medical | Venture Round | 0 |
| 3/2000 | MEDCHANNEL | Series B | 42M |
| 8/2007 | Molecular Partners | Series A | 15.6M |
| 12/2009 | Molecular Partners | Series B | 44.2M |
| 4/2014 | Binx Health | Series B | 0 |
| 7/2020 | CVRx | Private Equity Round | 0 |
| 8/2019 | CVRx | Series G | 93M |
| 11/2004 | Corthera | Series B | 15M |
| 5/2014 | Inspire Medical Systems | Series E | 0 |
| 7/2004 | Accumetrics | Series B | 0 |
| 7/2003 | Immunicon | Series F | 24.8M |
| 11/2014 | La Lumiere | Series B | 20M |
| 3/2007 | Orqis Medical | Series D | 12M |
| 1/2014 | TopiVert | Venture Round | 7.4M |
| 3/2007 | Axial Biotech | Series B | 15.3M |
| 4/2013 | ReVision Optics | Equity | 15M |
| 1/2014 | PowerVision | Series D | 0 |
| 12/2005 | Light Sciences Oncology | Series A | 32M |
| 3/2000 | Cyrano Sciences | Venture Round | 23M |
| 3/2009 | GetWellNetwork | Series C | 10M |
| 3/2000 | InfoMedics | Venture Round | 6M |
| 11/2011 | Biocartis | Series C | 95.8M |
| 7/2006 | InSound Medical | Series E | 18.9M |
| 4/2001 | Vascular Architects | Series C | 20M |
| 11/2009 | Spinal Modulation | Series C | 27.4M |
| 9/2014 | Inivata | Venture Round | 6.6M |
| 2/2008 | InSound Medical | Series E | 11M |
| 10/2009 | Direct Flow Medical | Series C | 40M |
| 3/2022 | Osteal Therapeutics | Series B | 0 |
| 12/2007 | Cardiac Dimensions | Series D | 0 |
| 11/2013 | Pulmocide | Series A | 27.6M |
| 10/2007 | Optherion | Series A | 37M |
| 1/2009 | Acclarent | Venture Round | 26M |
| 1/2002 | Sleep Solutions | Series E | 7M |
| 10/2009 | Sleep Solutions | Series F | 20M |
| 10/2003 | Sleep Solutions | Venture Round | 6.1M |
| 5/2000 | Sleep Solutions | Series C | 3M |
| 2/2013 | OptiScan Biomedical | Private Equity Round | 30.7M |
| 8/2009 | Neurosearch | Venture Round | 14.3M |
| 2/2009 | ImaCor | Series A | 0 |
| 9/2012 | Catalyst Biosciences | Post-IPO Equity | 13.4M |
| 2/2016 | Cala Health | Series B | 0 |
| 6/2010 | Aquinox Pharmaceuticals | Series B | 0 |
| 4/2002 | Replidyne | Series A | 13M |
| 4/2010 | Biocartis | Series B | 40M |
| 9/2014 | Biocartis | Series F | 0 |
| 12/2014 | Padlock Therapeutics | Series A | 23M |
| 1/2011 | 23andMe | Series C | 9M |
| 9/2002 | KuDOS Pharmaceuticals Ltd | Series C | 45.2M |
| 1/2012 | PowerVision | Series C | 12.5M |
| 10/2008 | Biolex Therapeutics | Series D | 0 |
| 1/2005 | Biolex Therapeutics | Venture Round | 8M |
| 6/2001 | NitroMed | Series E | 0 |
| 5/2002 | eNeura Therapeutics | Series A | 1M |
| 9/2004 | Vascular Architects | Series E | 0 |
| 8/2005 | 7TM Pharma | Venture Round | - |
| 6/2012 | PhaseBio Pharmaceuticals | Series B | 23M |
| 7/2013 | CVRx | Series F | 0 |
| 1/2009 | 7TM Pharma | Venture Round | 0 |
| 6/2007 | Aquinox Pharmaceuticals | Series A | 14.5M |
| 5/2007 | CVRx | Series D | 65M |
| 11/2009 | Celladon | Series C | 21.8M |
| 2/2012 | Celladon | Venture Round | 43M |
| 3/2005 | TorreyPines Therapeutics | Series C | 0 |
| 12/2012 | Biocartis | Series D | 0 |
| 6/2009 | Pronota | Series B | 7.4M |
| 1/2006 | Archus Orthopedics | Series C | 35M |
| 8/2003 | Biolex Therapeutics | Venture Round | 0 |
| 6/2013 | Vedanta Biosciences | Venture Round | - |
| 6/2013 | Protagonist Therapeutics | Series B | 0 |
| 11/2001 | Locus Pharmaceuticals | Series C | 0 |
| 11/2000 | Locus Pharmaceuticals | Series B | 0 |
| 3/2004 | InSound Medical | Series D | 17.2M |
| 3/2011 | Astute Medical | Series B | 13M |
| 11/2010 | 23andMe | Series C | 22.2M |
| 5/2010 | Breathe Technologies | Series C | 23M |
| 8/2008 | Neuron Systems | Series A | 9M |
| 5/2000 | Global Telemedix | Series B | 0 |
| 5/2010 | Astute Medical | Series B | 26.5M |
| 9/2009 | NovoCure | Venture Round | - |
| 8/2004 | Othera Pharmaceuticals | Series B | 0 |
| 6/2007 | 7TM Pharma | Series D | 22M |
| 3/2006 | 7TM Pharma | Series C | 0 |
| 9/2009 | Neotract | Series B | 28.1M |
| 10/2010 | Intio | Series B | 8.1M |
| 5/2012 | Mitralign | Series D | 0 |
| 4/2006 | Pronota | Series A | 7.8M |
| 1/2012 | Pronota | Series C | 4.8M |
| 3/2017 | Grail | Series B | 0 |
| 6/2011 | Spinal Modulation | Series D | 0 |
| 10/2003 | OmniSonics Medical Technologies | Series C | 43M |
| 7/2013 | ViaCyte | Series C | 10.6M |
| 11/2003 | CardioMEMS | Series B | 0 |
| 1/2003 | Vascular Architects | Series D | 0 |
| 5/2006 | ViaCyte | Venture Round | 0 |
| 1/2004 | Animas Corporation | Venture Round | 16.9M |
| 3/2003 | Sopherion Therapeutics | Series A | 0 |
| 7/2004 | Intrapace | Series C | 0 |
| 1/2010 | PhaseBio Pharmaceuticals | Series B | 25M |
| 5/2021 | Binx Health | Series E | 0 |
| 7/2000 | Lumenos | Series B | 34M |
| 7/2005 | Ilypsa | Series B | 36M |
| 12/2000 | InfoMedics | Venture Round | 10M |
| 5/2009 | iScience Interventional | Series F | 20.5M |
| 11/2010 | Syntaxin | Series C | 29M |
| 1/2008 | Arbor Surgical Technologies | Series C | 0 |
| 12/2007 | Mitralign | Series C | 0 |
| 10/2004 | Acuity Pharmaceuticals | Series B | 0 |
| 4/2013 | Aquinox Pharmaceuticals | Series C | 0 |
| 6/2014 | Aduro BioTech | Series C | 55.7M |
| 7/2008 | CVRx | Series E | 0 |
| 2/2014 | Thesan Pharmaceuticals | Series B | 49M |
| 3/2022 | Osteal Therapeutics | Series B | 0 |
| 5/2021 | Binx Health | Series E | 0 |
| 7/2020 | CVRx | Private Equity Round | 0 |
| 8/2019 | CVRx | Series G | 0 |
| 3/2017 | Grail | Series B | 0 |
| 2/2017 | Fusion Pharmaceuticals | Series A | 0 |
| 11/2016 | ReVision Optics | Venture Round | 0 |
| 2/2016 | Cala Health | Series B | 0 |
| 3/2015 | PhaseBio Pharmaceuticals | Series C | 0 |
| 1/2015 | Willow | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
